Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study

NCT02584933 · clinicaltrials.gov ↗

PHASE4

Phase

ACTIVE_NOT_RECRUITING

Status

233

Enrollment

INDUSTRY

Sponsor class

Conditions

ALK Positive Malignancies

Interventions

DRUG: ceritinib

Sponsor

Novartis Pharmaceuticals